| Literature DB >> 29854602 |
Asha Singh1, Mohd Yaqoob Dar2, Beenu Joshi3, Bhawna Sharma3, Sadhana Shrivastava1, Sangeeta Shukla1.
Abstract
This study aimed to treat hepatocellular ailments with biologically prepared silver nanoparticle (AgNPs). AgNPs were formulated using Morus alba leaf extract and their synthesis and characterization were determined by UV-visible spectroscopy, Transmission Electron Microscope (TEM), Scanning Electron microscope (SEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR) and Zeta analysis. In vitro studies on HepG2 cell lines for cytotoxic effect and in vivo studies in a rat model for hepatoprotective effect were carried out using biologically prepared AgNPs as curing agents. Dose response cytotoxicity on hepatic cancer (HepG2) cells was confirmed by 3-(4, 5-dimethyl thiazole-2-yl)-2, 5-diphenyl tetrazolium (MTT) assay. The inhibitory concentrations (IC50) were found to be 20 μg/mL and 80 μg/mL for AgNPs and M. alba leaf extract respectively against HepG2 cells at 24 h incubation. In addition, hepatotoxicity in Wistar rats (180 ± 10 g) was induced by intraperitoneal injection of N-nitrosodiethylamine (NDEA) and were treated with different doses of AgNPs (25, 50, 100 μg/kg). NDEA administration showed a significant rise in the biochemical parameters whereas the levels of enzymic antioxidants were decreased. Obtained results revealed that the elevated levels of Liver Function Test (LFTs) biomarkers were significantly reversed and the antioxidant levels were significantly recouped towards normal after the conjoint treatment of AgNPs in a dose-dependent manner. Thus green synthesized AgNPs showed a promising curing effect on hepatocellular ailments.Entities:
Keywords: HepG2; Liver; Morus alba; N-Nitrosodiethylamine; Silver nanoparticles
Year: 2018 PMID: 29854602 PMCID: PMC5977380 DOI: 10.1016/j.toxrep.2018.02.013
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Fig. 1Synthesis of silver nanoparticles under different range of temperatures (30 °C, 60 °C, 90 °C and 95 °C). (A) Colour change profile of hydrosol (B) UV–vis absorption spectrum of AgNPs.
Fig. 2Identification of Morphological characters of AgNPs (A) TEM micrograph, and (B) SEM micrograph of biosynthesized AgNPs.
Fig. 3Zeta potential of biosynthesized AgNPs.
Fig. 4Depiction of functional groups on AgNPs (A) FT-IR spectrum and (B) X-ray diffraction pattern.
Fig. 5Dose-dependent cytotoxicity (MTT assay) of AgNPs and M.alba extract against liver cancer cells with 24 h treatment compared with the standard anticancer drug (5-FU). Abbreviation: MTT, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium; AgNPs, Silver nanoparticles; M.alba, Morus alba; 5-FU, 5-Fluorouracil. Values are mean ± SD; N = 3; p ˂ 0.05 versus untreated control.
Therapeutic effect of AgNPs on LFTs biomarker against NDEA intoxication.
| Treatments | ALT (U/L) | ALP (U/L) | Albumin(g/dl) | T. Bilirubin (mg/dl) | γ-GT(U/L) |
|---|---|---|---|---|---|
| Control | 46.7 ± 2.5 | 178 ± 9.84 | 3.4 ± 0.18 | 0.26 ± 0.01 | 6.2 ± 0.34 |
| AgNPs | 46.0 ± 2.5 | 180 ± 9.95 | 3.5 ± 0.19 | 0.27 ± 0.01 | 6.0 ± 0.33 |
| NDEA | 210 ± 11.6 | 326 ± 18.0 | 1.8 ± 0.09 | 2.01 ± 0.11 | 19 ± 1.06 |
| NDEA + AgNPs 25 μg/kg | 98.4 ± 5.4 | 198 ± 10.9 | 3.0 ± 0.16 | 1.50 ± 0.08 | 13 ± 0.72 |
| NDEA + AgNPs 50 μg/kg | 69.5 ± 3.8 | 188 ± 10.4 | 3.2 ± 0.17 | 0.72 ± 0.03 | 9.6 ± 0.53 |
| NDEA + AgNPs 100 μg/kg | 56.8 ± 3.1 | 186 ± 10.3 | 3.3 ± 0.18 | 0.32 ± 0.01 | 7.0 ± 0.38 |
| NDEA + Sily 50 mg/kg | 48.2 ± 2.6 | 179 ± 9.90 | 3.5 ± 0.19 | 0.29 ± 0.01 | 6.8 ± 0.37 |
Abbreviation: NDEA, N-nitrosodiethylamine; AgNPs, Silver nanoparticles; Sily, Silymarin; ALT, Alanine aminotransferase. ALP, Alkaline phosphatase; γ-GT, Gamma-glutamyl transpeptidase.
@ Significant at 5% for ANOVA.
NDEA vs Control.
NDEA+ Therapy vs NDEA at P ≤ 0.05.
Protective effect of AgNPs on NDEA induced alterations in tissue biochemistry
| Treatments | GSH (U/L) | GSSG (U/L) | G-6-Pase(mg Pi/100 ml/min) | ATPase (μmole Pi/min/g liver) |
|---|---|---|---|---|
| Control | 7.6 ± 0.39 | 3.67 ± 0.20 | 6.80 ± 0.37 | 1971 ± 108 |
| AgNPs | 7.4 ± 0.40 | 3.92 ± 0.21 | 5.57 ± 0.30 | 1970 ± 108 |
| NDEA | 4.6 ± 0.25 | 18.9 ± 1.04 | 3.14 ± 0.17 | 849.0 ± 46.9 |
| NDEA + AgNPs 25 μg/kg | 6.5 ± 0.35 | 12.8 ± 0.71 | 4.08 ± 0.22 | 1242 ± 68.6 |
| NDEA + AgNPs 50 μg/kg | 6.8 ± 0.38 | 8.59 ± 0.47 | 4.71 ± 0.26 | 1350 ± 74.6 |
| NDEA + AgNPs 100 μg/kg | 7.2 ± 0.38 | 5.20 ± 0.28 | 5.32 ± 0.29 | 1560 ± 86.2 |
| NDEA + Sily 50 mg/kg | 7.3 ± 0.39 | 4.48 ± 0.24 | 5.42 ± 0.29 | 1650 ± 91.2 |
Abbreviation: NDEA, N-nitrosodiethylamine; AgNPs, Silver nanoparticles; Sily, Silymarin; GSH, Reduced glutathione; GSSG, Oxidised glutathione; G-6-Pase, Glucose-6-Phosphatase; ATPase, Adenosine triphosphatase.
@ Significant at 5% for ANOVA.
NDEA vs Control.
NDEA+ Therapy vs NDEA at P ≤ 0.05.
Fig. 6Photomicrographs of rat liver sections in the different experimental groups showing effect of NDEA and its subsequent treatment with different doses of AgNPS. A: Liver sections of control group, B: Liver of rat treated with NDEA, C: Liver of rat treated with AgNPs (25 μg/kg) after NDEA intoxication, D–E: Liver of rat treated with AgNPs (50 & 100 μg/kg) after NDEA intoxication, F: Liver of rat treated with Silymarin (50 mg/kg) after NDEA intoxication.